Neurocrine Biosciences (NASDAQ:NBIX) Downgraded by StockNews.com
StockNews.com lowered shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) from a strong-buy rating to a buy rating in a research note released on Friday morning. Several other research analysts also recently issued reports on NBIX. Piper Sandler upped their price target on shares of Neurocrine Biosciences from $95.00 to $100.00 and gave the stock […]
More Stories
The Future of AI in Entertainment: How AI Is Changing Online Casinos, Gaming, and Streaming
The entertainment sector is quickly changing with the integration of Artificial Intelligence (AI) by more and more companies – from...
J Heath Deneke Sells 1,000 Shares of Summit Midstream Corporation (NYSE:SMC) Stock
Summit Midstream Corporation (NYSE:SMC – Get Free Report) CEO J Heath Deneke sold 1,000 shares of the firm’s stock in...
Incyte Co. (NASDAQ:INCY) Receives Average Rating of “Hold” from Brokerages
Incyte Co. (NASDAQ:INCY – Get Free Report) has been assigned an average recommendation of “Hold” from the twenty ratings firms...
Eaton Co. plc (NYSE:ETN) Receives Average Rating of “Moderate Buy” from Brokerages
Eaton Co. plc (NYSE:ETN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seventeen...
NextEra Energy Partners, LP (NYSE:NEP) Given Consensus Recommendation of “Hold” by Analysts
NextEra Energy Partners, LP (NYSE:NEP – Get Free Report) has received a consensus rating of “Hold” from the seventeen analysts...
Analysts Set First Solar, Inc. (NASDAQ:FSLR) Target Price at $279.04
Shares of First Solar, Inc. (NASDAQ:FSLR – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the...